Section Arrow
Quote
MLYS.NASDAQ
- Mineralys Therapeutics
Quotes are at least 15-min delayed:2026/08/04 22:13 EDT
Regular Hours
Last
 26.5
+0.72 (+2.79%)
Day High 
26.58 
Prev. Close
25.78 
1-M High
31.11 
Volume 
663.83K 
Bid
24
Ask
27.5
Day Low
25.56 
Open
26.2 
1-M Low
24.945 
Market Cap 
2.27B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 26.62 
20-SMA 27.38 
50-SMA 26.95 
52-W High 47.65 
52-W Low 12.59 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.97/-1.42
Enterprise Value
2.27B
Balance Sheet
Book Value Per Share
7.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ENSCEnsysce Biosciences0.3842+0.1041+37.17%-- 
VTGNVistagen Therapeutics, Inc.0.3+0.055+22.45%-- 
RXRXRecursion Pharmaceuticals3.31+0.13+4.09%-- 
IBRXImmunityBio6.95-0.2-2.80%-- 
GOSSGossamer Bio0.1815+0.0079+4.55%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.